# Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

> **NCT02768532** · PHASE4 · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 47 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT02768532
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-01
- **Primary completion:** 2022-01-11
- **Final completion:** 2023-01-23
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** low inclusion rates
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768532, "Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02768532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*